Cagrilintide vs tirzepatide (Mounjaro/Zepbound) Mechanism: Cagrilintide: Amylin agonist Tirzepatide: Dual GIP/GLP-1 agonist Both novel approaches Weight loss: Cagrilintide: 10-12% monotherapy Tirzepatide: 15-22% monotherapy Tirzepatide superior as single agent Administration: Both: Weekly subcutaneous injection Both: Similar convenience Side effects: Cagrilintide: Strong GI effects Tirzepatide: Moderate GI effects Similar overall profile Approval status: Cagrilintide: Investigational Tirzepatide: FDA approved Tirzepatide available now Cost (when both available): Likely similar ($1,000-1,500/month) Both premium weight loss options Verdict: Currently, tirzepatide better choice (approved, superior weight loss)
The autism-associated MET receptor tyrosine kinase engages early neuronal growth mechanism and controls glutamatergic circuits development in the forebrain
Signs of an allergic reaction can include itchiness, a rash, hives, chest tightness, shortness of breath and swelling of the throat, lips, mouth or tongue
Hair benefits : Stimulates hair follicles Increases follicle size Extends anagen phase (growth phase) Improves blood flow to scalp Reduces inflammation affecting follicles Protocol : Topical : Apply to scalp daily Injectable : 1-2mg daily (systemic support) Expected results : Reduced shedding in 6-12 weeks, new growth visible in 4-6 months
